Activation of 5-HT4 receptors inhibits secretion of β-amyloid peptides and increases neuronal survival

Experimental Neurology

Volumn 203, Issue 1, 2007, Pages 274-278

  Cho, Seongeun ^a   Hu, Yun ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Cortex; Neuroprotection; Primary cultures; Soluble APP

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; AMYLOID PRECURSOR PROTEIN; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR;

ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TISSUE CULTURE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANILINE COMPOUNDS; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PIPERIDINES; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN; SEROTONIN AGONISTS; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 33751403136     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.07.021     Document Type: Article

References (26)

1. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., Barlow E., Ebert U., and Hillen H. Globular amyloid beta-peptide oligomer-A homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95 (2005) 834-847
2. Bockaert J., Sebben M., and Dumuis A. Pharmacological characterization of 5-hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. Mol. Pharmacol. 37 (1990) 408-411
3. Buttini M., Masliah E., Barbour R., Grajeda H., Motter R., Johnson-Wood K., Khan K., Seubert P., Freedman S., Schenk D., and Games D. {beta}-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's, disease. J. Neurosci. 25 (2005) 9096-9101 doi:10.1523/JNEUROSCI.1697-05.2005
4. Comery T.A., Martone R.L., Aschmies S., Atchison K.P., Diamantidis G., Gong X., Zhou H., Kreft A.F., Pangalos M.N., Sonnenberg-Reines J., Jacobsen J.S., and Marquis K.L. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 8898-8902
5. Consolo S., Arnaboldi S., Giorgi S., Russi G., and Ladinsky H. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. NeuroReport 5 (1994) 1230-1232
6. Dumuis A., Bouhelal R., Sebben M., Cory R., and Bockaert J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol. Pharmacol. 34 (1988) 880-887
7. Dupont L.J., Pype J.L., Demedts M.G., De Leyn P., Deneffe G., and Verleden G.M. The effects of 5-HT on cholinergic contraction in human airways in vitro. Eur. Respir. J. 14 (1999) 642-649
8. Fisher A., Michaelson D.M., Brandeis R., Haring R., Chapman S., and Pittel Z. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann. N. Y. Acad. Sci. 920 (2000) 315-320
9. Fontana D.J., Daniels S.E., Wong E.H., Clark R.D., and Eglen R.M. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology 36 (1997) 689-696
10. Harkany T., Abraham I., Konya C., Nyakas C., Zarandi M., Penke B., and Luiten P.G. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev. Neurosci. 11 (2000) 329-382
11. Hegde S.S., and Eglen R.M. Peripheral 5-HT4 receptors. FASEB J. 10 (1996) 1398-1407
12. Hock C., Maddalena A., Heuser I., Naber D., Oertel W., von der Kammer H., Wienrich M., Raschig A., Deng M., Growdon J.H., and Nitsch R.M. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann. N. Y. Acad. Sci. 920 (2000) 285-291
13. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
14. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., and Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56 (1997) 965-973
15. Kuo Y.-M., Emmerling M.R., Vigo-Pelfrey C., Kasunic T.C., Kirkpatrick J.B., Murdoch G.H., Ball M.J., and Roher A.E. Water-soluble Abeta(N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271 (1996) 4077-4081 doi:10.1074/jbc271.8.4077
16. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins 10.1073/pnas.95.11.6448. Proc. Natl. Acad. Sci. 95 (1998) 6448-6453
17. Lamirault L., and Simon H. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology 41 (2001) 844-853
18. Maillet M., Robert S.J., Cacquevel M., Gastineau M., Vivien D., Bertoglio J., Zugaza J.L., Fischmeister R., and Lezoualc'h F. Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat. Cell Biol. 5 (2003) 633-639
19. Matsumoto M., Togashi H., Mori K., Ueno K., Ohashi S., Kojima T., and Yoshioka M. Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J. Pharmacol. Exp. Ther. 296 (2001) 676-682
20. Medhurst A.D., Lezoualc'h F., Fischmeister R., Middlemiss D.N., and Sanger G.J. Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. Brain Res. Mol. Brain Res. 90 (2001) 125-134
21. Nakamura S., Murayama N., Noshita T., Annoura H., and Ohno T. Progressive brain dysfunction following intracerebroventricular infusion of beta1-42-amyloid peptide. Brain Res. 912 (2001) 128-136
22. Robert S.J., Zugaza J.L., Fischmeister R., Gardier A.M., and Lezoualc'h F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 276 (2001) 44881-44888
23. Rossner S., Beck M., Stahl T., Mendla K., Schliebs R., and Bigl V. Constitutive overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation. Eur. J. Neurosci. 12 (2000) 3191-3200
24. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
25. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., and Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24 (2004) 3592-3599
26. Turner P.R., O'Connor K., Tate W.P., and Abraham W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 70 (2003) 1-32